AI assistant
Zealand Pharma — Director's Dealing 2013
May 23, 2013
Preview isn't available for this file type.
Download source fileCopenhagen, 2013-05-23 10:24 CEST (GLOBE NEWSWIRE) -- Pursuant to the Danish
Securities Trading Act, section 28a, Zealand Pharma A/S (“Zealand”) shall
announce transactions in the company’s shares and related securities by
executives and persons/companies closely related to them.
In this regard, Zealand announces the following transaction:
Name: Jørgen Lindegaard
Reason: Vice chairman of the Board
Issuer: Zealand Pharma A/S
Type Shares
ISIN code: DK0060257814
Transaction: Purchase
Trading date: 22 May 2013
Market: NASDAQ OMX København A/S
Amount: 3,600
Price: DKK 75.50
Market value: DKK 271,800.00
Hereafter, Jørgen Lindegaard owns 14,285 shares in Zealand.
***
For further information, please contact:
David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300
Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate
Communications - Tel: +45 50 60 36 89, email: [email protected]
About Zealand
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology
company based in Copenhagen, Denmark. Zealand specializes in the discovery,
optimization and development of novel peptide drugs and has a broad and mature
pipeline of drug candidates identified through its own drug discovery
activities. The company’s focus lies in the field of diabetes/metabolic
diseases, and its lead drug invention is lixisenatide, a once-daily GLP-1
agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes.
Lixisenatide is approved in Europe (February 2013) under the name of Lyxumia®,
and under regulatory review in a large number of other countries globally,
including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2012).
Zealand has a partnering strategy for the development and commercialization of
its products and in addition to the collaboration with Sanofi in Type 2
diabetes, the company has partnerships with Boehringer Ingelheim in
diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and
AbbVie in acute kidney injury. For further information: www.zealandpharma.com